The median overall survival (OS) of NPC patients from the tumor TRIM31 (+++) positive group (median OS 32 months) was significantly shorter compared to those from the tumor TRIM31 (++) group (median OS 44 months), TRIM (+) group (median OS 76 months) and TRIM negative group (median OS NR months). The gene discussed is TRAT1; the disease is neoplasm.